The Prognostic Nutritional Index before durvalumab after chemoradiation predict the overall survival in patients with stage III non-small cell lung cancer

BACKGROUND: Adjuvant durvalumab after chemoradiation has become the standard of care for patients with stage III NSCLC, according to the PACIFIC trial. Whether biomarkers before durvalumab for patients with stage III NSCLC showed predictive and prognostic effects remains unknown. METHODS: This is a...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsuura, Shun, Serizawa, Sayaka, Yamashita, Ryoma, Morikawa, Keisuke, Ito, Yutaro, Hiramatsu, Toshiya, Mochizuki, Eisuke, Tanaka, Kazuki, Akiyama, Norimichi, Tsukui, Masaru, Koshimizu, Naoki, Kosugi, Takashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10101664/
https://www.ncbi.nlm.nih.gov/pubmed/37043179
http://dx.doi.org/10.1080/07853890.2023.2196089

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10101664/
https://www.ncbi.nlm.nih.gov/pubmed/37043179
http://dx.doi.org/10.1080/07853890.2023.2196089

Ejemplares similares